Advanced search
Publication Cover
Leukemia & Lymphoma Volume 46, 2005 - Issue 7
Submit an article Journal homepage
233
Views
43
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy

Agustin Avilés Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico; Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. MexicoCorrespondence[email protected]
,
Natividad Neri Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico; Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico
,
M Jesús Nambo Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico; Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico
,
Judith Huerta-Guzman Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico; Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico
,
Alejandra Talavera Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico; Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico
&
Sergio Cleto Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico; Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F. Mexico
Pages 1023-1028 | Received 17 Jan 2005, Published online: 03 Aug 2009

References

  • Aleman BMP, van del Belt-Dusebout AW, Kloktnan WJ, van't Veer MB, Bartelik H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431–3439.
  • Aviles A, Arévila N, Diaz-Maqueo JC, Gömez T, Garcia R, Nambo MJ. Late cardiac toxicity of doxorubicin, epirubicin and mitoxantrone therapy for Hodgkin's disease. Leuk Lymphoma 1993;11:275— 279.
  • Aviles A, Guzmán R, Talavera A, Garcia EL, Diaz-Maqueo JC. Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin and dacarbazine (EBVD) versus mitoxantrone, vinblastine, bleo-mycin and dacarbazine (MBVD). Med Pediatr Oncol 1994;22:168— 172.
  • Avilés A, Soto B, Guzmán R, Garcia EL, Nambo MJ, Diaz-Maqueo JC. Results of a randomized study of early Hodgkin's disease using ABVD, EBVD or MBVD. Med Pediatr Oncol 1995;23:171 — 175.
  • Cosset JM, Henry-Amar M, Pellae-Cosset B et al. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 1991;29:897–906.
  • Constine LS, Schwartz RG, Savage DE, King V, Muhs A. Cardiac function; perfusion and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997;21:447–449.
  • Graaf H, Willemze PHB, Van der Graff WTA, Sceijfer DTh, d'Uries EDG, Mulder NH. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer 1997;76:943–945.
  • Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer. Cancer 2003;97:1991 —1998.
  • Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1208–1215.
  • Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998;16:3592–3600.
  • Lind PA, Pagnateli R, Marck CB, Borges-Nieto S, Hu C, Zhou SM. Myocardial perfusion changes in patients irradiated for left-side breast cancer and correlation with coronary artery perfusion. Int J Radiat Oncol Biol Phys 2000;55:914–920.
  • Aviles A, Neri N, Cuadra I, Alvarado I, Cleto S. Second lethal events associated to treatment for Hodgkin's disease. A review of 2980 patients treated in a single Mexican Institute. Leuk Lymphoma 2000;39: 311— 319.
  • Ng AK, Bernard PM, Weiler E, Backstrand KC, Silver B, Marcus KC. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101–2108.
  • Lopez M. Dexrozasone. Current status and prospectives of cardiotoxicity of chemotherapy. Clin Ther 1999;15:37 — 49.
  • Lund MB, Kongeroud J, Be J, Abrahamsen AF, Ihlen H, Forfang K. Cardiopulmonary sequelae after treatment for Hodgkin's disease. Increased risk in females. Ann Oncol 1996;7:257— 264.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.